APLS
USDApellis Pharmaceuticals Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$20.400
Máximo
$20.610
Mínimo
$19.440
Volume
5.10M
Fundamentos da empresa
Capitalização de mercado
2.5B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
2.51M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals with a Neutral and lowers the price target from $24 to $19.
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $52 to $45.
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $50 to $45.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals with a Outperform and raises the price target from $50 to $52.
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $57 to $45.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals from Equal-Weight to Overweight and raises the price target from $29 to $32.
Ações relacionadas
RCG
RENN Fund Inc
RILYM
B. Riley Financial Inc. 6.375% Senior Notes due 2025
NGVT
Ingevity Corporation
GLV
Clough Global Dividend and Income Fund Common Shares of beneficial interest
SPXC
SPX Technologies Inc.
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.